logo
logo

RapidAI Announces $25 Million in Series B Funding to Expand AI-Enhanced Cerebrovascular Imaging Worldwide

Sep 17, 2020•almost 5 years ago

Amount Raised

$25 Million

Round Type

series b

Menlo ParkHealth CareManufacturing

Description

RapidAI, the worldwide leader in advanced imaging for stroke, today announced a $25 million Series B round of funding by Lennertz & Co. Building on years of profitability, these additional funds will accelerate the company’s strategic growth initiatives around the world.

Company Information

Company

Rapid Ai

Location

Menlo Park, California, United States

About

Legal Name of Rapid Ai is iSchemaView, Inc. RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. Leading the next evolution of clinical decision-making and patient workflow, RapidAI is empowering physicians to make faster decisions for better patient outcomes. Based on intelligence gained from over 10 million scans in more than 2,000 hospitals in over 100 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible. RapidAI — where AI meets patient care.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech